NEW YORK — A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.Five plaintiffs who seek to represent over 50,000 people who have sued J&J over its talc products filed the proposed class action in New Jersey federal court. 3 J&J has said that its baby powder an ...

Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.To begin with, the first has had notable growth in its markets, especially in the United States, due to its well-received product introductions and market penetration. The second one sustains its market leadership through effective operations and strong returns to shareholders while deliverin ...

Johnson & Johnson is a high-quality dividend stock.Johnson & Johnson (JNJ -0.14%) is dividend royalty. The healthcare behemoth has increased its dividend payment for 62 straight years. That puts it in the elite group of Dividend Kings, companies with 50 or more years of consecutive annual dividend growth.The healthcare stock also stands out for its higher dividend yield. With a nearly 3.3% forward dividend yield, an investment in Johnson & Johnson would generate more than double the dividend income of a sim ...

Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire private biotech Proteologix for $850 million in cash, with the potential for an additional milestone payment.The transaction is expected to be closed in mid-2024, subject to customary closing conditions.With the latest acquisition, JNJ is looking to boost its dermatology portfolio with an aim to address significant unmet needs in atopic dermatitis (AD), also known as eczema.Proteologix is engaged in developing bispe ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 5.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings Beat Estimates, Sales Miss ...

Johnson & Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 15, 2024 11:00 AM ET Company Participants Timothy Schmid - Executive Vice President and Worldwide Chairman of MedTech Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh We will get started. Hello everyone, and welcome to the 2024 RBC Capital Global Healthcare Conference. I’m Shagun Singh, Senior Medical Device Analyst at RBC. And I’m very pleased to have Johnson & Johnson here with us again this year. ...

Johnson & Johnson (NYSE:JNJ) BofA Securities Health Care Conference Transcript May 14, 2024 4:40 PM ET Executives John Reed - Executive Vice President, Innovative Medicine, R&D Analysts Geoff Meacham - Bank of America Charlie Yang - Bank of America Geoff Meacham The afternoon sessions of the first day of the BofA Healthcare Conference. My name is Geoff Meacham, I’m the Senior Biopharma Analyst here at BofA. And Charlie Yang from my team is on stage as well. So we’re thrilled today to have Johnson & Johnson ...

Johnson & Johnson (NYSE:JNJ) BofA Securities Health Care Conference Transcript May 14, 2024 4:40 PM ET Executives John Reed - Executive Vice President, Innovative Medicine, R&D Analysts Geoff Meacham - Bank of America Charlie Yang - Bank of America Geoff Meacham The afternoon sessions of the first day of the BofA Healthcare Conference. My name is Geoff Meacham, I’m the Senior Biopharma Analyst here at BofA. And Charlie Yang from my team is on stage as well. So we’re thrilled today to have Johnson & Johnson ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend ...

Kenvue (NYSE:KVUE) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE:JNJ) is selling its stake in the business.Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock. It is exchanging these shares for the indebtedness of JNJ held by Goldman Sachs & Co. LLC and J.P. Morgan.After this debt-for-equity exchange, the selling shareholders will sell the shares of KVUE stock to the underwriters of the ...